Publicacions
-
Borràs J; Ameijide A; Vilardell L; Valls J; Marcos-Gragera R; Izquierdo A
Evolución de la incidencia del cáncer en Cataluña, 1985-2002.
MEDICINA CLINICA 131 Suppl 1 11-18. .
-
Valls J; Grau M; Solé X; Hernández P; Montaner D; Dopazo J; Peinado MA; Capellá G; Moreno V; Pujana MA
CLEAR-test: combining inference for differential expression and variability in microarray data analysis.
Journal Of Biomedical Informatics 41 33-45. .
-
Menéndez M; González S; Obrador-Hevia A; Domínguez A; Pujol MJ; Valls J; Canela N; Blanco I; Torres A; Pineda-Lucena A; Moreno V; Bachs O; Capellá G
Functional characterization of the novel APC N1026S variant associated with attenuated familial adenomatous polyposis.
Gastroenterology 134 56-64. .
-
Hernández P; Huerta-Cepas J; Montaner D; Al-Shahrour F; Valls J; Gómez L; Capellá G; Dopazo J; Pujana MA
Evidence for systems-level molecular mechanisms of tumorigenesis.
Bmc Genomics 8 185-185. .
-
Molleví DG; Serrano T; Ginestà MM; Valls J; Torras J; Navarro M; Ramos E; Germà JR; Jaurrieta E; Moreno V; Figueras J; Capellà G; Villanueva A
Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
CARCINOGENESIS 28 1241-1246. .
-
Vendrell E; Ribas M; Valls J; Solé X; Grau M; Moreno V; Capellà G; Peinado MA
Genomic and transcriptomic prognostic factors in R0 Dukes B and C colorectal cancer patients.
INT J ONCOL 30 1099-1107. .
-
Salaverria I; Zettl A; Beà S; Moreno V; Valls J; Hartmann E; Ott G; Wright G; Lopez-Guillermo A; Chan WC; Weisenburger DD; Gascoyne RD; Grogan TM; Delabie J; Jaffe ES; Montserrat E; Muller-Hermelink HK; Staudt LM; Rosenwald A; Campo E
Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.
Journal of Clinical Oncology 25 1216-1222. .
-
Hernández P; Solé X; Valls J; Moreno V; Capellá G; Urruticoechea A; Pujana MA
Integrative analysis of a cancer somatic mutome.
MOLECULAR CANCER 6 13-13. .
-
Pujana MA; Ruiz A; Badenas C; Puig-Butille JA; Nadal M; Stark M; Gómez L; Valls J; Solé X; Hernández P; Cerrato C; Madrigal I; de Cid R; Aguilar H; Capellá G; Cal S; James MR; Walker GJ; Malvehy J; Milà M; Hayward NK; Estivill X; Puig S
Molecular characterization of a t(9;12)(p21;q13) balanced chromosome translocation in combination with integrative genomics analysis identifies C9orf14 as a candidate tumor-suppressor.
GENES CHROMOSOMES & CANCER 46 155-162. .
-
Pros E; Larriba S; López E; Ravella A; Gili ML; Kruyer H; Valls J; Serra E; Lázaro C
NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing.
HUM MUTAT 27 1104-1114. .
-
Solé X; Guinó E; Valls J; Iniesta R; Moreno V
SNPStats: a web tool for the analysis of association studies.
Bioinformatics 22 1928-1929. .
-
Montaner D; Tárraga J; Huerta-Cepas J; Burguet J; Vaquerizas JM; Conde L; Minguez P; Vera J; Mukherjee S; Valls J; Pujana MA; Alloza E; Herrero J; Al-Shahrour F; Dopazo J
Next station in microarray data analysis: GEPAS.
NUCLEIC ACIDS RESEARCH 34 -. .
Projectes
- Effects of intravenous iron therapy with ferric carboxymaltose compared with oral iron therapy in heart failure with preserved ejection fraction and iron deficency/ Efecto sobre la capacidad funcional del tratamiento con hierro intravenoso o hierro oral, comparado con placebo, en pacientes con insuficiencia cardiaca con fracción de eyección del ventrículo izquierdo preservada y anemia ferropénica
- Genomic approach for individualizing endometrial cancer diagnosis, prognosis and treatment
- VALIDACION DE ANEXINA 2 COMO PREDICTOR DE RECIDIVA EN EL CANCER DE ENDOMETRIO. DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS. ANXARECU
